bluebird bio, Inc. (BLUE)
BLUE Price and Sentiment
BLUE Latest news
This gene-therapy specialist may need some help turning things around.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that October 19, 2021 has been set as the record date for the dividend of shares of common stock of 2seventy to be distributed to bluebird stockholders in order to effect the separation of bluebird bio and 2seventy bio, Inc. into two independent, publicly traded companies. Each bluebird bio stockholder of record as of the close of business on October 19, 2021 will receive, on the distribution date, one share of
bluebird (BLUE) provides information on stock distribution ratio and cash allocation for the planned spin-off of the oncology business.
These once-promising biotech stocks are trading at a fraction of their all-time highs right now.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced the filing by 2seventy bio of an updated Form 10 Registration Statement with the U.S. Securities and Exchange Commission (SEC). This Form 10 reflects bluebird bio's plans for a tax-free spin-off of its oncology programs and portfolio into 2seventy bio as a publicly traded company. The spin-off is on track to be completed by early November 2021. bluebird bio also announced the appointment of Najoh Tita-Reid and
bluebird (BLUE) files BLA with the FDA for its gene therapy, betibeglogene autotemcel (beti-cel), in patients with transfusion-dependent ??-thalassemia.
Bluebird Bio Inc (NASDAQ: BLUE) completed the rolling submission of its marketing application to the FDA seeking approval for betibeglogene autotemcel (beti-cel) gene therapy. The application covers adult, adolescent, and pediatric patients with ?-thalassemia who require regular red blood cell (RBC) transfusions across all genotypes.
bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With ?-thalassemia Who Require Regular Red Blood Cell Transfusions2021-09-21 16:15
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (Nasdaq: BLUE) today announced it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for betibeglogene autotemcel (beti-cel) gene therapy in adult, adolescent and pediatric patients with ?-thalassemia who require regular red blood cell (RBC) transfusions, across all genotypes. The FDA previously granted beti-cel Orphan Drug status and Breakthrough Therapy designation
Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market. The post 7 Gene Editing Stocks Promising to Change our DNA appeared first on InvestorPlace.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, the planned oncology spin-off of bluebird bio (NASDAQ: BLUE) announced today that it will host a series of investor events to share further detail on its research pipeline and strategy. Session One: An Introduction to 2seventy's Pipeline; focus on AML [DARIC33] and Next-Gen Multiple Myeloma Strategy September 21, 2021, 11:00am-12:00pm ET Session Two: Focus on bNHL [bbT369] and Solid Tumor Strategy September 22, 2021, 1:00-2:00pm ET To access the